Pfizer and Kyowa Hakko collaborate on immuno-oncology combination study
US pharma major Pfizer (NYSE: PFE) and Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s PF-05082566 with mogamulizumab in a Phase Ib clinical study evaluating the safety and tolerability of the combination in patients with solid tumors.
PF-05082566 is an investigational, fully humanized monoclonal antibody (MAb) that stimulates signaling through 4-1BB (CD-137), a protein involved in regulation of immune cell activation, proliferation and survival. Kyowa Hakko Kirin’s anti-CCR4 antibody mogamulizumab suppresses some of the immune cells that shield the tumor from the immune system.
Companies to co-fund the study
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze